Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Concurrent Use of Crocin During Chemoradiation for Esophageal Squamous Cell Carcinoma

Cancer Invest. 2024 Feb;42(2):155-164. doi: 10.1080/07357907.2024.2319754. Epub 2024 Feb 22.

Abstract

Crocin is the major active carotenoid of saffron (Crocus sativus L.). Its pluripotent effects have led to a growing body of literature investigating its antitumor properties as well as its diverse potentials for mood stabilization, normal tissue protection, and inflammation reduction; However, there is a gap in clinical trials testing this substance in cancer patients. In this randomized, double-blind, placebo-controlled clinical trial, patients with newly diagnosed esophageal squamous cell carcinoma were randomly assigned to either 30 mg/day of crocin or placebo, prescribed during the neoadjuvant chemo-radiotherapy. The primary endpoints were pathological response and toxicity, and secondary endpoints were depression and anxiety levels and survival analysis.

Keywords: Esophageal squamous cell carcinoma; anxiety; carotenoids; chemotherapy; crocin; depression; radiotherapy.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Carotenoids / therapeutic use
  • Chemoradiotherapy
  • Double-Blind Method
  • Esophageal Neoplasms* / drug therapy
  • Esophageal Neoplasms* / radiotherapy
  • Esophageal Squamous Cell Carcinoma* / drug therapy
  • Humans

Substances

  • Carotenoids
  • crocin